Six years after CR and 38 months after the end of the chemotherapy, the patient presented a relapse with lymphadenopathies without central nervous or BM localisation. Cytogenetic analysis on BM cells after 24 h culture showed a t(8;9) translocation as a sole abnormality in 16/29 metaphases. A novel lymph-node biopsy confirmed the relapse of T lymphoblastic lymphoma with a TDT þ , CD2 þ , CD3 þ , CD4À, CD5 þ , CD7 þ , CD8À, CD10À, CD30À, CD1AÀ, KITÀ phenotype, and P53 moderate overexpression. A high mitotic activity was evidenced with MIB1 antibody. The search for an association with Epstein-Barr virus was negative with LMP antibody. A second CR was obtained after ALL-like induction chemotherapy with the same drugs plus L-asparaginase. After three courses of consolidation including high doses aracytine and methotrexate, autologous stem cell transplantation was done in February 2005. The patient is still in CR 7 months after the graft and the karyotype established on BM in June 2005 was normal on 30 metaphases.
The Notch pathway has a crucial role in embryonic development, determining cell fate of a range of different organs. In the hematopoietic system Notch-1 activation directs T-cell differentiation, and in murine models, constitutively activated intracellular Notch-1 (ICN) leads to T-cell leukemia. 1 In humans, there is evidence that Notch-1 dysregulation contributes to the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). For example, the t(7;9) translocation, whereby the promoter of the T-cell receptor b-chain is juxtaposed with Notch-1 producing constitutively activated ICN, has been described in a number of T-ALL patients, 2 and gain-of-function mutations in Notch-1 have recently been reported in 56% of pediatric/adolescent T-ALL patients. 3 The mutations affect two 'hotspot' regions -those in the highly conserved extracellular heterodimerization domain (HD) are thought to increase Notch-1 cleavage, whereas truncating mutations of the C-terminal PEST domain are thought to increase the intracytoplasmic half-life of ICN. 3 Although the phenotype of adult T-ALL is similar to its pediatric counterpart, there are significant differences; in particular it has a poorer prognosis, altered frequency of cytogenetic abnormalities and oncogene expression. 4 We were interested to know whether some of these differences could be attributed to the incidence and characteristics of Notch-1 mutations in adult patients, which may impact on signaling events downstream of Notch-1 and response to therapy. T-ALL in adults is relatively infrequent (approximately 20% of adult ALL patients) and there is limited data on Notch-1 mutations in these patients. To our knowledge there is just one study published in which five of 14 patients had mutations. 5 Two of the three mutations identified in the HD domain had been found in pediatric/adolescent patients, and both PEST domain mutations were novel and led to truncation of the C-terminal tail. We therefore screened presentation DNA samples from 24 adult T-ALL patients entered into the MRC UKALLXII trial for mutations in Notch-1 HD domains (both HD-N and HD-C), transactivation domain (TAD) and PEST domain using denaturing high-performance liquid chromatography (DHPLC) (Transgenomic WAVE s DNA fragment analysis system). Samples with an abnormal chromatograph were sequenced.
Overall, 17 patients (71%) had at least one Notch-1 mutation; 12 in the HD domain only, one in the PEST domain only, and four in both domains (Table 1) . Mutations in the HD-N domain were the most frequent, affecting over half of the patients (14/24, 58%), and tended to cluster in the highly conserved region between residues 1593 and 1597. Five had point mutations causing leucine to proline substitutions, which had been described in the pediatric/adolescent patients, 3 but seven had novel insertions or deletions, four of them complex alterations with contiguous insertions and deletions; all were in-frame. Cloning of products from one patient (#4) showed that the two leucine to proline mutations were on different alleles and were therefore either in trans or present in different cells. Five mutations were detected in the PEST domain; all were novel insertions and/or deletions that led to premature stop codons, either through a frameshift or through direct insertion of a stop codon, truncating the receptor by 39-119 amino acids. All lead to a truncated protein.
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Remission DNA samples were available from 15 patients, nine of whom had a mutation at disease presentation. In each case the mutation was no longer detectable in remission, confirming that these were acquired leukemia-specific mutations and not germline polymorphisms. Relapse DNA samples were available from four patients (#3, 7, 10 and 17, Table 1 ). The two patients with mutations at diagnosis relapsed with the same mutation(s). Neither acquired a different mutation, and the two patients who were wild type at diagnosis did not acquire a mutation at relapse.
The results in our cohort of patients are comparable with those reported in the younger aged patients (Table 2 ) and emphasise the heterogeneity of mutations that can disrupt Notch-1 function. Of the 18 different mutations identified, only four have been previously described in the pediatric cohort or T-ALL cell lines. 3 The HD domain is responsible for stable association of Notch-1 subunits 6 and structural integrity in this region is required to prevent exposure of the site to unregulated proteolytic cleavage. Functional analysis using a Notch-sensitive luciferase reporter assay has shown that leucine to proline point mutations in the HD domain lead to increased activity. 3 At least 10 of the 13 different HD domain mutations detected in our cohort are likely to result in an altered conformation, either through insertion of a proline residue, or loss or gain of amino acids. Conversely, the C-terminal PEST domain is an important negative regulatory site required for ICN degradation, and loss of this region also leads to increased activity in the Notch-sensitive reporter assay, probably through stabilization of ICN. 3 All PEST domain mutations detected in our patients would lead to a similarly truncated protein. The probable functional consequence of the mutations identified in our study is supported by the loss of these mutations at remission and reappearance at relapse, which provides conclusive evidence that they are acquired and are specifically associated with the leukemic clone. The selective expansion of such clones indicates that the mutations are likely to provide some proliferative or survival advantage to the cell.
The presence of mutations in our cohort was not restricted to the young adult patients; 10 of the mutant-positive patients were over 30 years of age at presentation, and median age of mutant-positive patients was 35 years compared to 20 years for wild-type patients. This suggests that a similar pathogenic mechanism underlies the development of most cases of T-ALL irrespective of age, and the difference in curability in the two groups is not related to a differing frequency of Notch mutations. The median presenting white cell count was 58.3 Â 10 9 /l and did not differ significantly between the two groups (P ¼ 70).
These results suggest that Notch mutations may be good candidate markers for minimal residual disease detection, particularly as they would not be susceptible to the antigenic drift that desensitizes current monitoring techniques in T-ALL. 7 Furthermore, g-secretase inhibitors (GSI) have been shown to induce cell cycle arrest in vitro in T-ALL cell lines harboring Notch-1 mutations 3 and therefore may offer a rational molecularly targeted approach for these patients who, in the older age group, have a poor outcome with current therapy. The experience gained from clinical trials using GSIs for Alzheimer's disease, where they inhibit the production of beta amyloid peptide from amyloid precursor protein, should expedite trials of these agents in T-ALL.
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas Gains and losses of genomic material are changes that play central roles in tumor development and progression. Comparative genomic hybridization (CGH) allows for the detection of over-and underrepresented sequences in tumor DNA as compared to normal DNA, and such genomic aberrations have been shown to have prognostic value in several studies of primary lymphomas. The serine/threonine kinase PIM1 is a known oncogene that has previously been shown to be
